Beijing Hotgen Biotech's Subsidiary Secures Beijing's "Specialized, Refined, Unique, and Innovative" SME Certification

Stock News05-07 21:20

Beijing Hotgen Biotech Co., Ltd. (688068.SH) has announced that its controlling subsidiary, Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (Shunjing Pharma), recently received a certificate from the Beijing Municipal Bureau of Economy and Information Technology. Shunjing Pharma has been recognized as a "Specialized, Refined, Unique, and Innovative" Small and Medium-sized Enterprise (SME) in Beijing, with the certification valid from April 2026 to April 2029.

The acquisition of this certification acknowledges Shunjing Pharma's technical expertise, innovation capabilities, and overall strength in the field of innovative biopharmaceuticals. This recognition is expected to enhance the core competitiveness and brand influence of both the parent company and its subsidiary. It will also contribute to the development of sustained innovation capacity and mechanisms, positively impacting and promoting the company's operational growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160493900?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160493900","market":"us","top_or_hot":-1,"title":"Beijing Hotgen Biotech's Subsidiary Secures Beijing's \"Specialized, Refined, Unique, and Innovative\" SME Certification","media":"Stock News","content":"<p>Beijing Hotgen Biotech Co., Ltd. (688068.SH) has announced that its controlling subsidiary, Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (Shunjing Pharma), recently received a certificate from the Beijing Municipal Bureau of Economy and Information Technology. Shunjing Pharma has been recognized as a \"Specialized, Refined, Unique, and Innovative\" Small and Medium-sized Enterprise (SME) in Beijing, with the certification valid from April 2026 to April 2029.</p>\n<p>The acquisition of this certification acknowledges Shunjing Pharma's technical expertise, innovation capabilities, and overall strength in the field of innovative biopharmaceuticals. This recognition is expected to enhance the core competitiveness and brand influence of both the parent company and its subsidiary. It will also contribute to the development of sustained innovation capacity and mechanisms, positively impacting and promoting the company's operational growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Hotgen Biotech's Subsidiary Secures Beijing's \"Specialized, Refined, Unique, and Innovative\" SME Certification</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Hotgen Biotech's Subsidiary Secures Beijing's \"Specialized, Refined, Unique, and Innovative\" SME Certification\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-07 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Hotgen Biotech Co., Ltd. (688068.SH) has announced that its controlling subsidiary, Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (Shunjing Pharma), recently received a certificate from the Beijing Municipal Bureau of Economy and Information Technology. Shunjing Pharma has been recognized as a \"Specialized, Refined, Unique, and Innovative\" Small and Medium-sized Enterprise (SME) in Beijing, with the certification valid from April 2026 to April 2029.</p>\n<p>The acquisition of this certification acknowledges Shunjing Pharma's technical expertise, innovation capabilities, and overall strength in the field of innovative biopharmaceuticals. This recognition is expected to enhance the core competitiveness and brand influence of both the parent company and its subsidiary. It will also contribute to the development of sustained innovation capacity and mechanisms, positively impacting and promoting the company's operational growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1160493900","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160493900","pubTimestamp":1778160019,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Hotgen Biotech Co., Ltd. (688068.SH) has announced that its controlling subsidiary, Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (Shunjing Pharma), recently received a certificate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","399267":"专精特新","688068":"热景生物","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","BK0239":"医药制造"},"translate_title":"北京霍特根生物子公司获得北京市“专、精、特、新”中小企业认证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"399267":1,"688068":1,"09939":1},"content_text":"Beijing Hotgen Biotech Co., Ltd. (688068.SH) has announced that its controlling subsidiary, Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (Shunjing Pharma), recently received a certificate from the Beijing Municipal Bureau of Economy and Information Technology. Shunjing Pharma has been recognized as a \"Specialized, Refined, Unique, and Innovative\" Small and Medium-sized Enterprise (SME) in Beijing, with the certification valid from April 2026 to April 2029.\nThe acquisition of this certification acknowledges Shunjing Pharma's technical expertise, innovation capabilities, and overall strength in the field of innovative biopharmaceuticals. This recognition is expected to enhance the core competitiveness and brand influence of both the parent company and its subsidiary. It will also contribute to the development of sustained innovation capacity and mechanisms, positively impacting and promoting the company's operational growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160493900","isCrawlerRequest":true}